Li X, et al. - Researchers designed a retrospective cohort of commercially insured adults in the USA diagnosed with PsO or PsA between 2015 and 2018 to investigate if initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is correlated with an improved risk of serious infection among real-world psoriasis (PsO) or psoriatic arthritis (PsA) patients. A sum of 11,560 new treatment episodes were recruited. They distinguished 190 serious infections (2% of treatment episodes) in 9264 person-years of follow-up. In biologic-naïve individuals with PsO or PsA, relative to TNF and IL-17, IL-12/23 inhibitors were correlated with a decreased risk of serious infection. No difference was found in infection risk across TNF, IL-17 or IL-12/23 inhibitors in biologic-experienced individuals.